INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$0.96
Market Cap
$29.72M
52W High
$2.60
52W Low
$0.89
ADV30
326,246
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,009,000 | -4,722,000 | 21,508,000 | 16,329,000 | 3,435,000 |
| Jun 2026 | 0 | — | -1,476,000 | -1,273,000 | 26,845,000 | 18,411,000 | 6,483,000 |
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,961,000
Investing CF
$-336,000
Financing CF
$816,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,717,000
Inventory
—
Receivables
$4,767,000
ST Investments
—
EBIT TTM
$-20,195,000
Pretax Income TTM
$-18,416,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-10,046,875
Enterprise Value
$15,604,702
Total Cash
$18,411,000
Total Debt
$1,405,000
Shares Out
30,959,079
Trailing EPS
$-0.60
Book Value
$0.89
ROE
-74.8%
ROA
-39.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | 23,524,000 | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | 32,097,000 | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | 38,139,000 | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | 60,104,000 | -22,686,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-18,416,000
OpCashFlow TTM
—
Assets (Latest)
$26,845,000
Forward EPS
$-0.43
Max Pain — expiry 2027-03-19
max pain strike: $1.00 · spot: $1.03 · call oi: 1,097 · put oi: 73Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $30.80M | $3.31 | — |
| SAEN | Genenta Science S.p.A. | $27.82M | $0.58 | — |
| CVM | CEL SCI CORP | $32.54M | $1.85 | — |
| PTHS | Pelthos Therapeutics Inc. | $26.89M | $6.84 | — |
| GNTA | Genenta Science S.p.A. | $33.03M | $0.69 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio (INMB) Q3 2026 Earnings Call Transcript
2026-11-06 17:17 · Yahoo
INmune Bio, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
INmune Bio Inc (INMB) Q3 2026 Earnings Call Highlights: UK Approval Path for Ebstracell Narrows ...
2026-11-06 11:17 · Yahoo
INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
2026-11-05 21:00 · Yahoo
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
2026-10-29 13:15 · Yahoo
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
2026-10-28 12:00 · Yahoo
Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel
2026-10-21 18:28 · Yahoo
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
2026-10-21 11:15 · Yahoo
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
2026-10-21 11:00 · Yahoo
Can Quantum Computing (QUBT) Be A Bargain As Its INmune Bio Deal Opens Biopharma?
2026-10-16 04:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.